Literature DB >> 2048150

Neuromuscular effects of nigexine, a basic phospholipase A2 from Naja nigricollis venom.

E G Rowan1, A L Harvey, A Menez.   

Abstract

Nigexine is a basic phospholipase A2 from the venom of the spitting cobra Naja nigricollis. In addition to its anticoagulant and cytolytic properties, nigexine also affects neuromuscular transmission in vitro. On chick biventer cervicis preparations, 1.5 microM nigexine caused a slowly developing block of responses to nerve stimulation, and a progressive loss of postjunctional sensitivity. Nigexine was at least 10 times less potent than notexin. On frog cutaneous pectoris preparations, nigexine caused a transient facilitation of evoked acetylcholine release, followed by a block. Spontaneous release was not abolished, and nigexine induced the release of abnormally large packets of transmitter. Nigexine also caused contracture of muscle fibres, accompanied by depolarization and degeneration. Nigexine appears to be able to cause prejunctional blockade and direct muscle damage to isolated skeletal muscle preparations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2048150     DOI: 10.1016/0041-0101(91)90290-8

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  2 in total

1.  Neurotoxicity and other pharmacological activities of the snake venom phospholipase A2 OS2: the N-terminal region is more important than enzymatic activity.

Authors:  Morgane Rouault; Lachlan D Rash; Pierre Escoubas; Eric Boilard; James Bollinger; Bruno Lomonte; Thomas Maurin; Carole Guillaume; Stéphane Canaan; Christiane Deregnaucourt; Joseph Schrével; Alain Doglio; José María Gutiérrez; Michel Lazdunski; Michael H Gelb; Gérard Lambeau
Journal:  Biochemistry       Date:  2006-05-09       Impact factor: 3.162

2.  Proteomic characterization of Naja mandalayensis venom.

Authors:  Emídio Beraldo; Guilherme Rabelo Coelho; Juliana Mozer Sciani; Daniel Carvalho Pimenta
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2021-07-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.